Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,348 recruiting studies in this area right now.
By phase
- Not applicable9,612
- Phase 24,442
- Phase 12,685
- Phase 1/Phase 21,654
- Phase 31,400
- Phase 2/Phase 3287
- Phase 4268
Top conditions
- Breast Cancer1,207
- Prostate Cancer648
- Cancer636
- Colorectal Cancer476
- Lung Cancer421
- Ovarian Cancer341
- Multiple Myeloma329
- Pancreatic Cancer288
- Gastric Cancer285
- Acute Myeloid Leukemia283
- Hepatocellular Carcinoma259
- Solid Tumor245
- Advanced Solid Tumor231
- Head and Neck Cancer227
- Cervical Cancer225
- Endometrial Cancer213
- Advanced Solid Tumors208
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center458
- Fudan University306
- National Cancer Institute (NCI)294
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University275
- Mayo Clinic237
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences145
- AstraZeneca132
- Ruijin Hospital129
Where studies are running
- California1,401
- Texas636
- Arizona508
- Florida439
- Alabama430
- New York406
- Massachusetts340
- Maryland330
- New Jersey275
- Pennsylvania236
Recruiting studies20,348 total
- NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Bullhead City, ArizonaAges 18 years+ - NCT05655312RecruitingPhase 1/Phase 2
Targeted radiation melanoma treatment with or without nivolumab
This early-stage study tests whether a targeted radioactive drug can shrink advanced melanoma, either alone or along with nivolumab (an immune-activating medicine). You may be eligible if your melanoma shows a specific target on scan imaging and has progressed despite prior melanoma treatments.
Orange, CaliforniaAges 18–90 - NCT05652686RecruitingPhase 1/Phase 2
Studying PT217 for neuroendocrine cancers
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
Duarte, CaliforniaAges 18 years+ - NCT05657743Recruiting
Radiation seeds study for advanced pancreatic cancer safety
This trial tests a radiation treatment that places tiny radioactive seeds directly into the tumor to treat advanced pancreatic cancer. It mainly focuses on safety and whether the treatment can be delivered effectively, especially for people who may not be able to have more chemotherapy or surgery.
HolonAges 18 years+ - NCT05642455RecruitingPhase 1/Phase 2
Study of a new treatment for certain childhood cancers
This Phase 1/2 study tests a new therapy for children and young adults with specific types of cancer that have been treated with chemotherapy before. It may help by targeting cancer features in the tumor and using your immune system in a controlled way.
Palo Alto, CaliforniaAges 2–21 - NCT05671822RecruitingPhase 2
Study of targeted drugs for HER2-positive advanced stomach cancer
This Phase 2 trial tests whether SHR-A1811—given with other medicines—works safely and effectively for people with advanced stomach or gastroesophageal junction cancer that has high HER2. It may help shrink tumors or slow cancer growth, especially if previous treatment didn’t work.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05664009Recruiting
Testing Redsenol-1 Plus for cancer-related fatigue
This trial tests a natural supplement for fatigue in cancer survivors. You must have had fatigue for at least a month and be otherwise stable.
London, OntarioAges 18 years+ - NCT05641259RecruitingPhase 1
LP-108 with azacitidine for blood cancers
This trial tests a new drug called LP-108 combined with azacitidine for people with certain blood cancers like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It aims to see if the combination is safe and helps shrink or control the cancer.
NanchangAges 18 years+ - NCT05652335RecruitingPhase 1
JNJ-79635322 for hard-to-treat myeloma or amyloidosis
This Phase 1 study tests how safe and how well JNJ-79635322 works in people with multiple myeloma that has come back or is resistant to treatment, or AL amyloidosis that has already been treated. It may help by targeting cancer cells and abnormal proteins driving these diseases.
Duarte, CaliforniaAges 18 years+ - NCT05640102Recruiting
Study of zanubrutinib in Waldenström macroglobulinemia
This is an observational study that follows people with Waldenström macroglobulinemia (WM) to learn how well zanubrutinib works and how safe it is. Your results will be tracked in relation to your disease features, including a blood/marrow marker called MYD88.
Huntsville, AlabamaAges 18 years+ - NCT05669989Enrolling by invitationPhase 2
Continuing isatuximab treatment for multiple myeloma
This study allows people with multiple myeloma who are already benefiting from the drug isatuximab in an earlier clinical trial to keep receiving it after that trial ends. It is an extension study, meaning you can continue your treatment without interruption.
St Louis, MissouriAges 18 years+ - NCT05646862RecruitingPhase 3
Comparing two treatments for advanced breast cancer with a PIK3CA mutation
This trial tests whether a new drug combo (inavolisib plus fulvestrant) works better than an existing one (alpelisib plus fulvestrant) for people with a specific type of advanced breast cancer that has a PIK3CA mutation. It aims to find a treatment that may help control the cancer longer.
Greenbrae, CaliforniaAges 18 years+ - NCT05636514RecruitingPhase 1
Testing epigenetic and sensitizer treatment for AML and MDS
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
Sydney, New South WalesAges 18 years+ - NCT05654246Recruiting
ShareForCures breast cancer support and research program
This trial is for adults with breast cancer (or suspected breast cancer) who can take part in an English-language program in the United States. It aims to understand and improve outcomes for people affected by breast cancer.
Dallas, TexasAges 18 years+ - NCT05653622RecruitingPhase 2
FDOPA PET–guided radiation planning for glioblastoma patients
This Phase 2 trial tests a radiation “planning” approach guided by an FDOPA PET scan. It aims to better target glioblastoma tissue in people who can’t follow the standard STUPP treatment plan.
Nancy, DeAges 18 years+ - NCT05641831RecruitingPhase 2
Canakinumab to prevent clonal blood count problems turning into cancer
This Phase 2 study tests canakinumab to help stop high-risk clonal cytopenias of unknown significance (CCUS) from progressing into a blood cancer. If you have persistent low blood counts and specific genetic features, this treatment may lower the chance of progression.
Miami, FloridaAges 18 years+ - NCT05642884Recruiting
Pre-surgery program for older adults getting stem cell transplant
This study checks whether a “pre-surgery” health coaching program is practical and safe for older people with multiple myeloma who are scheduled for an autologous stem cell transplant. It may help patients prepare better for transplant recovery, and the study will see if the plan can be carried out smoothly.
Birmingham, AlabamaAges 60 years+ - NCT05669820RecruitingPhase 2/Phase 3
Study drug for aggressive brain tumor after surgery
This trial tests an “antisecretory factor” treatment in people with grade 4 glioblastoma (or astrocytoma). It aims to see whether it can improve outcomes when used alongside planned cancer treatments after surgery.
LundAges 18–75 - NCT05647265RecruitingPhase 2
Immunotherapy before surgery for sarcomatoid pleural mesothelioma
This trial tests adding immunotherapy before surgery to help patients with sarcomatoid pleural mesothelioma. The goal is to shrink or control the cancer and make surgery possible, while checking safety.
Anchorage, AlaskaAges 18 years+ - NCT05656794RecruitingPhase 2
Radiation after treatment for prostate cancer that has spread
This trial studies whether adding a targeted course of radiation to the prostate area after initial systemic treatment can improve outcomes for people with metastatic prostate cancer. It may help control the cancer by treating remaining disease after medicines have started working.
Toronto, OntarioAges 18–100 - NCT05656235RecruitingPhase 2
Study of keeping kidneys longer in upper tract bladder cancer
This Phase 2 trial studies whether a combination treatment can control high-grade upper tract urothelial cancer without removing the kidney and ureter (radical nephroureterectomy). It may help people who must avoid surgery or choose not to have it because of medical risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05665504Recruiting
Biomarker test for managing early lung nodules after treatment
This study looks at lung “biomarkers” (test results from your nodule/tissue) to better predict risk of cancer coming back and to guide long-term follow-up. It may help doctors choose the best surveillance plan after surgery or other treatment for early, potentially curable lung cancer.
Tampa, FloridaAges 18 years+ - NCT05639972RecruitingPhase 1/Phase 2
HPV cancer trial using immune T cells made for you
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
New Brunswick, New JerseyAges 18 years+ - NCT05668884RecruitingPhase 2
Testing three drugs for advanced bile duct cancer
This Phase 2 trial tests a combination of three medicines (GEMOX, donafenib, and tislelizumab) for advanced bile duct cancer. It aims to see if the treatment can shrink tumors and improve outcomes in people with certain tumor stage and health test results.
Shanghai, Shanghai MunicipalityAges 18–75
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,348 recruiting oncology studies from the U.S. registry right now, out of 31,535 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.